Literature DB >> 25926430

Ethnic variability in the expression of hepatic drug transporters: absolute quantification by an optimized targeted quantitative proteomic approach.

Kuan-wei Peng1, James Bacon1, Ming Zheng1, Yingying Guo1, Michael Zhuo Wang2.   

Abstract

Hepatic OATPs 1B1, 1B3 and 2B1, as well as P-gp, play important roles in regulating liver uptake and biliary excretion of drugs. The intrinsic ethnic variability in OATP1B1-mediated hepatic uptake of statins has been proposed to underlie the ethnic variability in plasma exposures of statins between Caucasians and Asians. Using a targeted quantitative proteomic approach, we determined hepatic protein concentrations of OATP1B1, OATP1B3, OATP2B1, P-gp, and PMCA4 (a housekeeping protein) in a panel of human livers (n = 141) and compared protein expression across Caucasian, Asian, African-American, and unidentified donors. Using an optimized protocol that included sodium deoxycholate as a membrane protein solubilizer, the hepatic protein expression levels (mean ± S.D.) of these transporters across all livers were determined to be 15.0 ± 6.0, 16.1 ± 8.1, 4.1 ± 1.3, 0.6 ± 0.2, and 2.4 ± 1.0 fmol/μg of total membrane protein, respectively. The scaling factor was 3.5 mg of total membrane protein in 100 mg of wet liver tissue. OATP1B1 protein expression was significantly associated with the c.388A>G (rs2306283, N130D) single nucleotide polymorphism. When compared across ethnicity, the hepatic expression levels of OATP1B1 and OATP1B3 were unexpectedly higher in Asians relative to Caucasians, suggesting that hepatic OATP expression alone does not explain the increased systemic statin levels in Asians compared with Caucasians. These findings may help improve physiologically based pharmacokinetic modeling to predict statin pharmacokinetic profiles and enable extrapolation of pharmacokinetic data of OATP substrates across ethnic groups.
Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25926430     DOI: 10.1124/dmd.115.063362

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  21 in total

1.  Quantification of Four Efflux Drug Transporters in Liver and Kidney Across Species Using Targeted Quantitative Proteomics by Isotope Dilution NanoLC-MS/MS.

Authors:  John K Fallon; Philip C Smith; Cindy Q Xia; Mi-Sook Kim
Journal:  Pharm Res       Date:  2016-06-29       Impact factor: 4.200

2.  Toward a Consensus on Applying Quantitative Liquid Chromatography-Tandem Mass Spectrometry Proteomics in Translational Pharmacology Research: A White Paper.

Authors:  Bhagwat Prasad; Brahim Achour; Per Artursson; Cornelis E C A Hop; Yurong Lai; Philip C Smith; Jill Barber; Jacek R Wisniewski; Daniel Spellman; Yasuo Uchida; Michael A Zientek; Jashvant D Unadkat; Amin Rostami-Hodjegan
Journal:  Clin Pharmacol Ther       Date:  2019-07-26       Impact factor: 6.875

3.  Strategies of Drug Transporter Quantitation by LC-MS: Importance of Peptide Selection and Digestion Efficiency.

Authors:  Buyun Chen; Liling Liu; Hoangdung Ho; Yuan Chen; Ze Yang; Xiaorong Liang; Jian Payandeh; Brian Dean; Cornelis E C A Hop; Yuzhong Deng
Journal:  AAPS J       Date:  2017-06-06       Impact factor: 4.009

4.  Quantification of Neonatal Fc Receptor and Beta-2 Microglobulin in Human Liver Tissues by Ultraperformance Liquid Chromatography-Multiple Reaction Monitoring-based Targeted Quantitative Proteomics for Applications in Biotherapeutic Physiologically-based Pharmacokinetic Models.

Authors:  Xiazi Qiu; Michael Zhuo Wang
Journal:  Drug Metab Dispos       Date:  2020-07-28       Impact factor: 3.922

5.  Organic Anion Transporting Polypeptides Contribute to the Disposition of Perfluoroalkyl Acids in Humans and Rats.

Authors:  Wen Zhao; Jeremiah D Zitzow; Yi Weaver; David J Ehresman; Shu-Ching Chang; John L Butenhoff; Bruno Hagenbuch
Journal:  Toxicol Sci       Date:  2017-03-01       Impact factor: 4.849

6.  Advancing Predictions of Tissue and Intracellular Drug Concentrations Using In Vitro, Imaging and Physiologically Based Pharmacokinetic Modeling Approaches.

Authors:  Yingying Guo; Xiaoyan Chu; Neil J Parrott; Kim L R Brouwer; Vicky Hsu; Swati Nagar; Pär Matsson; Pradeep Sharma; Jan Snoeys; Yuichi Sugiyama; Daniel Tatosian; Jashvant D Unadkat; Shiew-Mei Huang; Aleksandra Galetin
Journal:  Clin Pharmacol Ther       Date:  2018-09-12       Impact factor: 6.875

Review 7.  Interindividual and interethnic variability in drug disposition: polymorphisms in organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1).

Authors:  Hannah H Lee; Richard H Ho
Journal:  Br J Clin Pharmacol       Date:  2017-01-19       Impact factor: 4.335

8.  Rosuvastatin Pharmacokinetics in Asian and White Subjects Wild Type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions.

Authors:  Hsin-Fang Wu; Nadya Hristeva; Jae Chang; Xiaorong Liang; Ruina Li; Lynda Frassetto; Leslie Z Benet
Journal:  J Pharm Sci       Date:  2017-04-03       Impact factor: 3.534

Review 9.  Pharmacogenetics of Lipid-Lowering Agents: Precision or Indecision Medicine?

Authors:  Jeffrey E Alfonsi; Robert A Hegele; Steven E Gryn
Journal:  Curr Atheroscler Rep       Date:  2016-05       Impact factor: 5.113

10.  Protein Expression and Functional Relevance of Efflux and Uptake Drug Transporters at the Blood-Brain Barrier of Human Brain and Glioblastoma.

Authors:  Xun Bao; Jianmei Wu; Youming Xie; Seongho Kim; Sharon Michelhaugh; Jun Jiang; Sandeep Mittal; Nader Sanai; Jing Li
Journal:  Clin Pharmacol Ther       Date:  2019-12-10       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.